BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26139471)

  • 1. Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo.
    Nishioka C; Ikezoe T; Yokoyama A
    Cancer Med; 2015 Sep; 4(9):1426-31. PubMed ID: 26139471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
    Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
    Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Takeuchi A; Nobumoto A; Tsuda M; Yokoyama A
    Leukemia; 2015 Dec; 29(12):2296-306. PubMed ID: 26260387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Pan B; Xu K; Yokoyama A
    Cancer Sci; 2017 Apr; 108(4):685-695. PubMed ID: 28107581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A versatile drug delivery system using streptavidin-tagged pegylated liposomes and biotinylated biomaterials.
    Chen MH; Soda Y; Izawa K; Kobayashi S; Tani K; Maruyama K; Tojo A; Asano S
    Int J Pharm; 2013 Sep; 454(1):478-85. PubMed ID: 23806815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
    Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
    Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
    Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitizing AML cells by targeting bone marrow endothelial cells.
    Bosse RC; Wasserstrom B; Meacham A; Wise E; Drusbosky L; Walter GA; Chaplin DJ; Siemann DW; Purich DL; Cogle CR
    Exp Hematol; 2016 May; 44(5):363-377.e5. PubMed ID: 26898708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.
    Humeniuk R; Menon LG; Mishra PJ; Saydam G; Longo-Sorbello GS; Elisseyeff Y; Lewis LD; Aracil M; Jimeno J; Bertino JR; Banerjee D
    Leukemia; 2007 Dec; 21(12):2399-405. PubMed ID: 17713546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.